BVT Call 260 BIIB 20.09.2024/ DE000VM38453 /
5/17/2024 8:54:00 AM | Chg.-0.160 | Bid10:00:06 PM | Ask10:00:06 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.810EUR | -16.49% | - Bid Size: - |
- Ask Size: - |
Biogen Inc | 260.00 USD | 9/20/2024 | Call |
GlobeNewswire
5/16
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...
GlobeNewswire
5/15
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire
5/9
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire
5/8
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
5/7
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
4/29
Muscular Dystrophy Association Launches ALS Awareness Month with Public Service Announcement ‘Answer...
GlobeNewswire
4/25
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...
GlobeNewswire
4/23
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...